MTOR and juvenile myelomonocytic leukemia: In addition, preclinical evidence suggests a potential therapeutic role for mTOR inhibition in JMML.9 In this case report, we describe an infant with JMML status post-HSCT with evidence of graft loss and disease recurrence, but currently doing well following withdrawal of immunosuppression and initiation of rapamycin.